IMV.TO

IMV Inc. [IMV.TO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IMV.TO Stock Summary

In the News

IMV.TO Financial details

Company Rating
-
Market Cap
13.12M
Income
-36.73M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
29 Sep 2023
P/E
-42.73
Forward P/E
-
PEG
13.24
P/S
-
P/B
-104.47
P/C
-
P/FCF
-0.58
Quick Ratio
2.46
Current Ratio
2.93
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.42
EPS next Y
-
EPS next Q
-
EPS this Y
-12.28%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
2.53%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-98.82%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-51%
ROE
250%
ROC
-0.83%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.62-13.1
52W High
-
52W Low
-
RSI
-
Rel Volume
1.14
Avg Volume
13.81K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.52236
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
AAPL
MSFT
EMBASSY.NS
CMC.DE
LLY.DE
Same Sector
SDGR
CRVW
CRXM
600594.SS
ERYP.PA
Check Those
XLK
BRLA.L
1851.HK
0637.HK
IMAQ
Similar Market Cap
RBND
ZIN.L
INPX
DVP
LFI.L

Company Profile

Healthcare Biotechnology
  • Volume Average 13.81K
  • Market Capitalization 13.12M
  • Employee 63
  • CEO Mr. Andrew Hall M.Sc.
  • Headquarters Dartmouth,NS,CA
  • IPO Date 2007-10-24
  • Website https://www.imv-inc.com

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.